Intraoperative blood salvage: a new trend in blood transfusion medicine
The organization of a program of intraoperative blood salvage (lOBS) lOBS is playing an increasing role in modern medical practice. A great variety of solutions have been applied for lOBS in different clinical settings and blood banking systems. These solutions depend on the lOBS system employed, cultural environment, credit given to the safety of homologous blood, homologous blood availability and cost, apheresis experience, and experience both with conventional autotransfusion and lOBS.
There are two main policies for lOBS: a) Since lOBS devices are used in the operating room and the anesthesiologist plays a key role in blood replacement for surgical patients, autotransfusion systems are under the anesthesiologist's direct supervision. This happens mostly when non-mechanical systems for lOBS are employed but also with the mechanical devices, especially automatic ones. Often there is no link between the people interested in lOBS and the staff of the blood bank whose task is merely to satisfy the needs for supplemental homologous blood products. b) Since autodonation, apheresis and cell washing are typical tasks of the personnel working in blood transfusion centers, lOBS is considered part of the duties of the experts in transfusion medicine and several transfusion services take full responsibility for establishing lOBS programs, integrated in their autotransfusion programs.
In 1980, Lonser and Taber (1) demonstrated the feasibility of an lOBS program in a community hospital setting. With a study that began in November 1985, the Southern Arizona Regional Red Cross Blood Bank (2) demonstrated that an active intraoperative autotransfusion program could be offered by a single blood bank to all hospitals in metropolitan Tucson. In the same study, to further reduce the requirements for homologous blood products, autologous platelet rich plasma was collected in theperioperative period, mostly from patients undergoing cardiopulmonary bypass surgery.
At San Martino Hospital in Genoa we have similar experience and we feel it is irrelevant whether lOBS is controlled by the anesthesiologist or the immunohematologist. What is important is that long-term success of the program is ensured and that the efforts of dedicated people assure that the opportunities and benefits of autologous transfusion are kept available to appropriate candidates.
Impact of lOBS on blood transfusion services (BTS)
lOBS may have considerable impact on BTS since it has to be fitted into the autotransfusion program. The BTS has to adapt its general organization, and its personnel to this task 24h a day, to rationalize all the phases of the procedure, to render the system cost-effective, and to adapt the lOBS devices to the real needs of each single unit since these devices are designed to meet a specific need. Staff has to be trained and training must be kept up-to-date. Cooperation with surgical teams is essential both in implementing the system and keeping it working at an optimal level.
Medical presence in the operating room may be unnecessary but supervision has to be guaranteed. If lOBS is in the hands of the anesthesiologist its impact on the BTS may be minimal except for reduction of reliance on homologous blood products. Specific examples of this reduction are easy to find but unnecessary. In general terms it can be stated that a "mature" autotransfusion system can reduce homologous blood requirements by 25-30%, half of which is met with lOBS. This means a reduction in laboratory backup for blood collection and follow-up of transfusion reactions-immunizations-infections transmitted with blood, reduction of look-back programs, safer blood transfusion and possibility of shifting donors from conventional donation to platelet and plasma apheresis.
The unit that offers lOBS must avoid its frivolous use since the procedure is costly in terms of harnesses and medical time. Moreover, when setting up a program, cooperation between the BTS and surgical units is crucial in a common comprehensive effort to ensure blood transfusion meets patients real needs.
Mechanical lOBS devices
lOBS devices were developed in the sixties and were widely used during the Vietnam war by Klebanoff (3, 4) , who employed Bentley open-heart machinery to anticoagulate, filter and reinfuse shed blood during surgery. This experience led eventually to the development of today's devices.
Commercially available lOBS devices (Haemonetics, Dideco, Electromedics, BRAT, Shiley) are based on the principle of discontinuous flow cell separators. During the operation, shed blood is anticoagulated and drawn by suction into a sterile, filtered reservoir. Filtration removes macro and micro-debris such as clots, bone, fat, bowel content and microaggregates of formed elements. The shed blood is then processed in a bowl in Which, by centrifugation, the red blood cells are separated from other fluids and debris and washed with saline. The concentrated erythrocytes are washed and are ready for reinfusion to the patient throughout surgery.
The volume of the bowl (125, 175,225,375 ml) and the number of passes required to complete the procedure depend on the type of operation and volume of blood that is shed. Some devices are manual and others automated; to process one unit of red blood cells (225 ml) it takes approximately 10 to 15 minutes with manual and 4 to 6 minutes with automatic equipment.
After washing, saline-suspended, plasma and anticoagulant free packed red blood cells with hematocrit 50 to 65% are ready for transfusion, usually by gravity.
Most lOBS equipment can be supplemented with a rapid reinfusion pump that is particularly useful in the management of hypovolemic shock or massive intraoperative blood losses that are common in liver transplantation or vascular surgery. A similar system, that anticipated commercial ones, was introduced at Baylor College of Medicine in the early eighties.
lOBS machines require trained technicians to set up and monitor the blood processing. With automatic equipment the automated washing cycle eases operation requirements and can be handled by nursing or anesthesia personnel, but supervision is still required. Their use may be inappropriate for patients with massive bleeding because blood processing and washing takes too long and may be unnecessary or disadvantageous when massive bleeding is taking place.
One device per patient per operating room is the rule with lOBS equipment, although one device may be used for multiple operating rooms when only moderate blood loss is expected. More than one device per operating room may be needed in particular conditions such as liver transplantation.
Other mechanical systems not exclusively aimed at lOBS can be used for cell saving, such as most multipurpose cell separators and the Cobe-IBM 2991 cell washer. While cell separators are of limited use as lOBS equipment, the Cobe-IBM 2991 has found widespread application in its semiautomatic or fully automatic types.
Blood is collected from the operatory field, filtered and sent into a cardiotomy reservoir or a Sorensontype system, drained into the washing bag of the processor that, after completion of the washing cycle, can be used to return blood to the patient. From 10 to 15 minutes are required for processing 500 ml of blood, with little supervision if the automatic model is employed.
The Cobe-IBM 2991, like the other mechanical lOBS devices, is too big to transport easily from one operating room to another in the same hospital or among different hospitals served by the same lOBS unit. A recent innovation from Haemonetics, namely the "Cell Saver Haemolite" has been recently introduced to overcome this problem: it weighs only 40 pounds, so transport is much easier. The machine is of the manual type and employs a granade bowl (200-275 ml capacity), and is not as effective as regular-size lOBS devices. It is mostly aimed at red blood cell saving in elective orthopedic and vascular surgery. It is designed to function alongside any intra or post-operative collection device for blood salvaging from drainages as in orthopedic surgery, or for processing shed mediastinal blood after cardiac surgery. These advantages are offset by the lack of automation that marks a step backwards in the Haemonetics general policy.
Non-mechanical lOBS devices
A simple system for lOBS, developed by the Sorenson Research Corporation (6) can be used as an alternative to mechanical systems. This apparatus, that can be easily incorporated into standard suction systems found in operating rooms, consists in a receptacle cannister containing a 2-liter collection bag with CPO anticoagulant into which, after filtration on a 170/1 screen filter, blood is aspirated through a special suction tip. When the bag is full, anticoagulated shed blood can be used for transfusion. The infusion rate, usually driven by gravity, can be increased by a pressure cuff. A similar apparatus, the Solcotrans, is another drainage-suction system with a low turbulence flow pathway in which ACO-A is used for anticoagulation and a 40 /1 microporous filter is added to allow reinfusion of aspirated blood.
Both the Sorenson and Solcotrans -and other similar systems (Pleurevac and Emerson) -can be used for post-operative autotransfusion. With easy transportation their common advantage is that the cost is competitive and that no dedicated personnel is required. With their inadequacy for major bleeding their common disadvantage is that salvaged blood cells are not washed and concentrated in normal procedures. As a consequence dilution of blood, presence of anticoagulant, free hemoglobin, activated platelets and coagulation factors, cell debris, fat microemboli, and bacteria are inherent risks of this system and theoretically, if grossly contaminated blood is salvaged, the potential risks may outweigh the benefits of autotransfusion. In reality, however, thousands of patients have been autotransfused with these devices without incident (7-9).
Combinations of mechanical and non-mechanical lOBS devices
In theoretical terms the choice of an autotransfusion system depends on the rate of bleeding. When bleeding is slow and regular a collection and processing system should be preferred. When bleeding is acute and massive, and the RBC product does not need washing only a collection and autotransfusion system may be needed since the time required for complete blood processing would contribute to an unacceptable level of hypotension. As a consequence a combination of the two systems should be considered the best option for any kind of patients. With present systems and costs, however this solution is not to be applicable everywhere, but in very specific conditions, organ transplantation in primis, it is essential.
Experimental systems for lOBS
Another method for autotransfusing shed blood has been recently described (10) . The system, built around a hollow-fiber hemoconcentrator, may become easy to use, highly efficient to cope with major bleeding and cost competitive.
Firstly ACO-A anticoagulated-saline diluted blood is sucked into a standard cardiotomy reservoir. Blood is processed with a Gambro BC 140 dialysis filter in which salvaged blood is circulated by the action of a roller pump, with a capacity of 500 ml/min. Water, solutes, anticoagulant and low molecular weight blood components (less than 80,000 dalton) are filtered off while red blood cells and useful plasmaproteins with coagulation factors and platelets are concentrated and reinfused.
Red blood cells can be concentrated to a desired hematocrit by recirculating blood through the filter. If clinically safe, the system may become the first continuous flow technique for intraoperative blood collection and washing. An additional advantage may be that the autotransfusate contains sufficient amounts of coagulation factors and platelets to make the use of homologous products unnecessary.
Quality and quantity of the product
As to the quality of the product it is always important to indicate whether a given system washes and concentrates salvaged red blood cells (RBC) or not. Only the mechanical lOBS devices, operated according to the manufacturer's directions, wash and concentrate salvaged RBC. Washing removes most activated platelets and coagulation factors, tissue thromboplastins, cell debris, free hemoglobin and anticoagulant solutions. The RBC are concentrated at hematocrits from 50 to 65% so that fluid excess can be avoided. RBC morphology, resistance to osmotic shock, deformability of washed cells as well as 2-3 OPG and ATP levels are normal (11) suggesting that younger, healthier cells survive the harvest procedures and that these cells may even be superior to stored homologous RBC (12) .
When more than three units of salvaged RBC are used these advantages may be offset by the appearance of dilution coagulopathy with platelet loss, prolongation of activated prothrornbo-plastin time, thrombin time and -more important -diminished levels of antithrombin III, Protein C and S that may contribute to thrombotic phenomena unless homologous fresh plasma is used along with platelets. In this condition, the main advantage of autotransfusion, namely non-exposure to viruses, may be lost unless autologous products are obtained before operation as a part of the autodonation system (13) .
The quality of the salvaged blood obtained with the Sorenson-Solcotrans system appears to be less satisfactory. Blood is obtained directly from the operatory field, mixed with rinsing solutions and anticoagulants. The level of free hemoglobin may be acceptable (9, 14) or not, even reaching levels of 1600 mg/dl (15) with hemolysis resulting from vacuum-induced trauma, contact of blood with air and tissues, kinking of the tubings, foaming in tubing and reservoir, and turbulent blood flow. Platelet loss is constant as is platelet and coagulation factors activation. Nonetheless, from a clinical point of view, this diluted blood (hct from 20 to 38%) has been safely and effectively used in aortic and thoracic surgery, hip replacement, ectopic pregnancies, spleen and liver fractures, without any untoward changes in the basic coagulation parameters or patient's clinical condition (16) (17) (18) .
As to the quality of salvaged blood obtained with the hollow-fiber hemoconcentrators no human study has been presented so far and the data are too scanty to permit any conclusion.
There is no real limit to the amount of blood that can be salvaged, washed and reinfused with the mechanical lOBS devices, provided that adequate protein-platelet support is given. In a case of liver transplantation, in a patient with anti-c and antl-Jk" antibodies, we have salvaged 67 units of packed RBC by employing 2 machines and a rapid reinfusion system on-line.
To reduce costs, there is general agreement that mechanical lOBS devices are to be used when more 6 than two units of packed RBC are to be salvaged. When the anticipated blood loss is less, the SorensonSolcotrans system is a good alternative. It must also be clear that with mechanical lOBS devices the cost of a single procedure is almost independent of the volume of blood processed but the procedure becomes more and more cost effective as the volume of blood salvaged becomes larger. With the Sorenson-Solcotrans systems, costs may depend on the volume of blood salvaged.
Safety
Considerable experience with the newest lOBS systems confirms the safety of lOBS that is routine in many clinical settings. Nonetheless alteration in blood composition and costituents is always possible, of the same type as during apheresis or extra-corporeal blood circulation procedures. These alterations depend on psycho-chemical as well as human factors. Blood is salvaged from the operatory field through the action of a vacuum and circulated through pumps, tubings, filters, connectors; it is spun and reinfused under pressure. The mechanical fragility of the RBC can be increased by excessive vacuum-induced trauma, cavitation phenomena, foaming in tubing, turbulent blood flow, kinking of tubing, malfunction of peristaltic pumps, inadequate anticoagulation of blood, that alone or in combination, can induce immediate hemolysis or shortened RBC survival time.
At the same time excessive anticoagulation with ACO, dilution with saline, contact of blood with air and tissues, may contribute to RBC damage that may become apparent immediately during lOBS or in the days after, with increased hemoglobinemia and drop in hematocrit or hemoglobin levels.
Washing salvaged blood eliminates plasma and proteins and coagulation factors but platelets are lost along with cell debris. As a consequence, if large amounts of blood are processed and reinfused, hypoproteinemia and dilution coagulopathy may be induced. This can make replacement necessary with platelets and fresh plasma, most of all for its content of antithrombin III, C and S proteins. In this case if homologous products are used the main advantages of lOBS are lost. Nonetheless, in most operations no coagulation disorder is seen, confirming the experimental demonstration that disseminated intravascular coagulation can largely be prevented in baboons by washing the autologous blood to remove thromboplastic substances (19) . Even if this is not done, as with the Sorenson-Solcotrans system, no grossly abnormal coagulation disorders are seen (16-18) -thrombocytopenia-thrombocytopathy excluded as typically seen in cardiac surgery (20) . Microembolization and air embolism are no longer a problem with present-day devices.
Potential adverse effects of lOBS include sepsis and spread of malignancy. Besides clinical experience several studies support the feasibility of lOBS with patients with contaminated wounds (21-23) when washing techniques are used and antibiotics added to washing solutions. Nonetheless the risk of sepsis is real since, as shown by Bourdeux (22) cell washing only partially removes blood contamination. As to the spread of malignancies, it is generally accepted that lOBS salvages malignant cells along with RBC as shown by Yaw (24) . This possibility is counter balanced by the risk of immunodepression caused by homologous blood transfusion (25) (26) (27) (28) (29) . The topic remains controversial and controlled trials are needed.
Equally controversial is the length of time that the salvaged blood can be stored ... If the red cells are washed, no opsonic activity remains to protect against bacterial contamination and no nutrient or preservative is present unless intentionally introduced in the reinfusion bag. The risk of bacterial contamination is inherent with the discontinuous flow centrifuge (DFC) systems. Storage for 24h appears to be a safe compromise as with most washed cellular products. In this condition proper labelling is essential. The Authors are not aware of any study on the feasibility and utility of cryopreservation of salvaged RBC.
Newer applications of mechanical lOBS machines
With these devices, the processing of salvaged RBC removes autologous proteins, coagulation factors and platelets that, as in all types of massive transfusion, have to be replaced. This creates the paradoxical condition that a successful RBC autotransfusion can generate the need for homologous plasma and platelets. Typically this happens in cardiac surgery where the problems of dilution coagulopathy are magnified by the effects on coagulation factors and platelets of prolonged exposure to foreign surfaces, roller pumps, oxygenators and drugs, and by neutrophil degranulation with release of elastase (30) . The role of platelets in this Iatrogenic disorder is central and an acquired von Willebrand-Iike disorder has been described with adequate response to DDVAP or platelet concentrates (31) .
If homologous platelets and plasma are used the advantages of lOBS may be lost and the risks of developing viral disorders, particularly non-A non-B hepatitis, are obvious and depend on the number of homologous units employed and on the local prevalence of the viral disorder among donors and recipients. The probability of contracting hepatitis was calculated as 1.3% for one unit of homologous blood, to up to 10.6% for three units and to 22% for more than three (32) . Exposure to homologous blood products can be avoided if autologous platelets and plasma are prepared in the week before surgery. These procedures are safe. Plasma collection is possible in the course of predeposit autodonation but platelets have to be collected in the 24 h before the operation using regular cellular cell separators. In these conditions platelets and plasma are an extra cost that has to be paid to avoid exposure to homologous blood products.
lOBS devices are in principle discontinuous flow centrifuges. There is thus no real difficulty in using them for apheresis and a system has been described that if used, with lOBS and recovery from drainages or oxygenator lines, in the preoperative period allows hemodilution and platelet rich plasma collection with the same machine and harness that will be used for lOBS (33) . Before extracorporeal blood circulation a catheter is inserted into the superior cava and ACD-A anticoagulated blood is aspirated into the bowl of an lOBS machine. The bowl is spun at 4800 rpm, and plasma is separated from buffy-coat and packed RBC. When plasma comes close to reaching the exit of the bowl the air bag is closed and plasma is diverted to a separate collection bag. When the buffycoat reaches the bowl exit the plasma bag is closed and the platelet layer collected into a different bag. Saline is used for bowl washing and RBC dilution, and saline-suspended RBC are collected into a blood reinfusion bag from which they are either reinfused or saved for intraoperative requirements, depending on the patient's preoperative hematocrit. The volume of these blood components depends on the number of passes made which, in turn, depends on the patient's preoperative hematological conditions.
In an initial study with 15 patients whose hematocrit exceeded 35% before cardiac surgery, from one to three units of saline-suspended packed RBC were collected together with 1.62 x 10 11 thrombocytes and 459 ml of plasma in 3.1 passes (33) . The catheter is then disconnected and replaced with a suction tip for standard lOBS through a filtered reservoir. lOBS is carried out according to the normal protocol, and blood that remains in the oxygenator at the end of the operation is concentrated routinely. Since 1986 more than 600 procedures have been carried out in patients undergoing heart surgery, organ transplantation or major orthopedic surgery. In approximately 85% of these patients the risks of homologous blood were completely eliminated and in the remaining 15% reduced drastically. The San Martino Hospital experience with cardiac patients in 1987 is summarized in the table below which compares homologous blood product requirements in a group of patients receiving conventional transfusion support and in similar groups of patients after predeposit autodonation combined with lOBS alone or else lOBS and autologous platelet and plasma support. It is clear that a successful outcome of the autodonation-IOBS program cannot be guaranteed for all patients. Success requires the patient to be correctly informed by his physician, early information must be available as a basis for scheduling elective surgery and the patient's condition must be good enough to permit autodonation and lOBS. Another essential condition is ease of access, both in terms of the patient's ability to carry out predeposit autodonation and preoperative hemodilution and in terms of organization of the transfusion service so that personnel is available to deal with urgent lOBS requirements.
CONCLUSIONS
Autotransfusion systems nowadays, are not so much aimed at solving the problem of blood procurement, as at reducing the risks of homologous blood products. These risks include viral disorders, bacterial and protozoal disease transmission, alloimmunization and reactions to blood components and even detrimental effects on survival of patients with malignancies.
Autotransfusion does not compete with homologous transfusions or with established and functioning blood collection systems. It will never replace homologous Intraoperative blood salvage (lOBS) is the technical side of the autotransfusion "cascade" that begins with predeposit autodonation and intentional preoperative hemodilution and continues in the operating room with lOBS and salvage from drainages. Like for predeposit donation, some fundamental rules (35) have to be followed in its application: -the patient must be in sufficiently good clinical condition; -the expected needs cannot be satisfied by predeposit autodonation; -the expected needs must be known and lOBS machines used when considerable blood loss is anticipated; -a forecast must be made of what blood components are expected to be needed; -the most suitable technique must be established and matched to the type of surgical procedure; -the staff has to be well trained; -lOBS is no longer an experimental or investigational procedure; -over-use of these procedures should be avoided by keeping a watchful eye open for "frivolous" requests. If these requirements are satisfied not only can lOBS avoid transfusion reactions and disease transmission but it can reduce demand on blood bank supply, offer fresh erythrocytes with high oxygen transport capacity, it is cost-effective, avoids alloimmunization, is essential with polyimmunized patients for whom it is difficult to find large volumes of compatible blood or for people who refuse homologous transfusions such as Jehovah's witnesses.
Paradoxically lOBS is more popular among anesthesiologists than blood bankers. Recently the topic was covered by Stehling et al. (36) as a survey of transfusion practices among American anesthesiologists, to be used as a basis for formulating future educational activities by the Committee on Blood and Blood Products of the American Society of Anesthesiologists.
Certainly transfusion medicine has entered a new phase marked by renewed appreciation of the risks of homologous transfusion. With public concern about the possibility of transmission of AIDS through blood, medical attention is now focussed on finding out the potential impact of autologous blood donation in transfusion programs and on the international blood economy. In 1980, only one out of ten U.S. hospitals reported the use of autologous blood (37) . In 1988, almost all the 200 regional blood centers in the United States offered an autologous predeposit service to patients and some institutions offered an lOBS service as well (36) . Competition between homologous blood banks and autologous blood services seems to be over. 
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